evan weekli dose therapi video updat
overal sector modestli outperform xbi ibb nbi vs
best perform coverag regeneron worst perform mirati
januari confer preview see full note
aimmun expect palforzia approv launch late januari possibl
earlier expect increment detail launch plan well updat interact
payer regul
anticip quieter expect commentari recent beigen
collabor china well updat otezla integr prior year use
highlight upcom pipelin mileston across portfolio like new cfo peter
griffith first major investor event sinc assum role januari look detail
strateg prioriti
biogen expect focu aducanumab look increment color
file timelin interact regul compani typic use provid
updat strategi may get addit color earlier neurosci pipelin
galapago filgotinib look updat commerci buildout feedback kol
payer engag may get increment time detail earlier pipelin includ proof-of-
concept trial initi toledo asset
gilead filgotinib file us expect compani provid detail
commerci plan may get increment time detail uc top-line readout phase
initi ankylos spondyl last year compani highlight upcom pipelin event
set stage new ceo oday start march year well look detail
manag strategi re-acceler growth particularli bd capit alloc prioriti
neg readout behind us expect broader strateg updat
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
think new disclosur unlik next meaning catalyst expect later
year
mirati expect rel unev mirati last year compani provid
 overview confer look increment detail timelin updat
data sitravatinib interim analysi insight strateg prioriti newli
neurocrin compani like pre-announc ingrezza sale data
 consensu estim investor weve spoken discuss
possibl neurocrin may start give sale guidanc believ less like
due occasion volatil caus season contract may get detail
compani interact regul vy-aadc program
regeneron compani may pre-announc us eylea sale in-lin
consensu forecast unlik provid financi guidanc
prior year may get updat emerg novel oncolog portfolio believ
becom increasingli import driver compani
vertex compani typic use deliv updat overal strategi believ
incom ceo/curr reshma kewalramani like outlin vision strateg prioriti
next year ahead manag transit may get increment detail
trikafta launch progress
gilead thursday gilead announc acquir exclus licens portfolio broadli
neutral antibodi hiv rockefel univers rockefel receiv up-front
payment elig receiv cumul mileston payment well royalti net sale
addit rockefel retain right perform non-clin early-stag clinic research
portfolio hiv antibodi
regeneron regeneron announc posit phase data garetosmab fop believ
data encourag given ultra-rar diseas us patient lack treatment option
despit show statist signific endpoint total lesion activ regeneron intend
use data support potenti regulatori file encourag regeneron expect
garetosmab minim
impact share given limit commerci opportun
estim garetosmab could drive ww peak sale approv link note
 continu announc acquisit dermira cash premium
volume-weight averag trade price transact expect close
expand lilli immunolog pipelin dermatolog portfolio
biogen biogen announc enter collabor therapeut
collabor leverag gene circuitri platform aim identifi dial
express disease-associ gene within microgli cell primari immun cell
central nervou system implic variou neurolog neurodegen diseas
term agreement receiv up-front payment
elig receiv develop mileston payment well potenti royalti
charl martineau pm univers toronto compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
